Citation Impact
Citing Papers
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
2014
Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine
2006
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
2012
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
SARS and MERS: recent insights into emerging coronaviruses
2016 Standout
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
2003 Standout
Clinical trial: the efficacy and safety of oral PF‐03491390, a pancaspase inhibitor – a randomized placebo‐controlled study in patients with chronic hepatitis C
2010
Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’
2014
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
2005 Standout
Cost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations
2011
Treatment responses in Asians and Caucasians with chronic hepatitis C infection
2008
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures
2010 StandoutNobel
Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy
2011
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells
2010 StandoutNobel
Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
2012
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
2010
Hepatic steatosis in obese patients: clinical aspects and prognostic significance
2004
Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
2010
IL28B and the Control of Hepatitis C Virus Infection
2010
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Role of liver biopsy in management of chronic hepatitis C: A systematic review
2002
Antiviral treatment of hepatitis C
2014
Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment
2006
Interferon-based therapy of hepatitis C
2007
Interferon-based therapy for chronic hepatitis C: current and future perspectives
2008
Treating viral hepatitis C: efficacy, side effects, and complications
2006
A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In Vivo
2011 StandoutNobel
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
Interferon Lambda Alleles Predict Innate Antiviral Immune Responses and Hepatitis C Virus Permissiveness
2014 StandoutNobel
Antiviral therapy for chronic hepatitis C: past, present, and future
2006
Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
2008
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
2010
Mechanisms of action of ribavirin against distinct viruses
2005
Priming of hepatitis C virus-specific cytotoxic t lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA
2000 StandoutNobel
Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
2011
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy
2011
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
2007
Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy
2005
American Gastroenterological Association Technical Review on the Management of Hepatitis C
2006
Interferon lambdas: the next cytokine storm
2011
IL28B single nucleotide polymorphisms in the treatment of hepatitis C
2011
Expert opinion on the treatment of patients with chronic hepatitis C
2008
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
2011
Hepatitis C virus: How genetic variability affects pathobiology of disease
2011
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
2010
Genetics of IL28B and HCV—response to infection and treatment
2012
Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment
2011
Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation
2010
The global NAFLD epidemic
2013 Standout
IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza
2014 StandoutNobel
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
2010
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
2011 Standout
Diagnosis and management of chronic viral hepatitis: Antigens, antibodies and viral genomes
2008
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Hepatitis C pharmacogenetics: State of the art in 2010
2010
Optimal therapy in genotype 1 patients
2009
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
2010
IL28B rs12979860 Genotype and Spontaneous Clearance of Hepatitis C Virus in a Multi-Ethnic Cohort of Injection Drug Users: Evidence for a Supra-Additive Association
2011
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B
2012
Replication of hepatitis C virus
2007 StandoutNobel
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients
2017 StandoutNobel
Polymorphisms in melanoma differentiation‐associated gene 5 link protein function to clearance of hepatitis C virus
2014 StandoutNobel
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction
2013
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection
2008
Internal Initiation Stimulates Production of p8 Minicore, a Member of a Newly Discovered Family of Hepatitis C Virus Core Protein Isoforms
2009 StandoutNobel
The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit
2010 StandoutNobel
2013
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
Studying Hepatitis C Virus: Making the Best of a Bad Virus
2007 StandoutNobel
Antisense Gets a Grip on miR-122 in Chimpanzees
2010 StandoutNobel
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
2013
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
2012
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Role of liver biopsy in management of chronic hepatitis C: A systematic review
2002
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C
2006
Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate
2015 StandoutNobel
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
2007
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
Towards a small animal model for hepatitis C
2009 StandoutNobel
Alanine Scanning of the Hepatitis C Virus Core Protein Reveals Numerous Residues Essential for Production of Infectious Virus
2007 StandoutNobel
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Treatment of Chronic Viral Hepatitis
2001
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Works of Vito Carretta being referenced
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
2007
An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response
2010
A Randomized Trial of Amantadine and Interferon Versus Interferon Alone As Initial Treatment for Chronic Hepatitis C
2001
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection #
2008
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
2005
A randomized controlled trial of pegylated interferon α‐2a (40 KD) or interferon α‐2a plus ribavirin and amantadine vs interferon α‐2a and ribavirin in treatment‐naïve patients with chronic hepatitis C
2005
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg‐interferon α‐2b and ribavirin
2010
Efficacy of 5 MU of interferon in combination with ribavirin for naıve patients with chronic hepatitis C virus: a randomized controlled trial
2001